ReviewACS pharmacology & translational science2026
Diabetes-Associated Cognitive Dysfunction: Pathophysiology, Molecular Mechanisms, and Emerging Therapeutic Strategies.
Review in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes-associated cognitive dysfunction (DACD), which includes memory loss, executive dysfunction, attention, processing speed, and an increased risk of dementia, is a growing problem associated with diabetes mellitus (DM), especially type 2 diabetes mellitus. Due to a significant increase in the global burden of diabetes and population ageing, DACD is becoming an important public health issue. This review provides a comprehensive overview of the pathophysiology, molecular mechanisms, biomarkers, experimental models, and emerging therapeutic strategies associated with DACD. At present, it is believed that the multiple mechanisms associated with chronic hyperglycemia, insulin resistance, oxidative stress, mitochondrial dysfunction, neuroinflammation, blood-brain barrier disruption, and microvascular injury all contribute to the pathogenesis of DACD. These interrelated mechanisms are responsible for cognitive decline, synaptic dysfunction, and neuronal damage. Experimental research has shown that specific molecular pathways contribute to the pathogenesis of DACD, such as AGE-RAGE signaling, nuclear factor-κB activation, PI3K/Akt dysregulation, and inflammatory cascades. Emerging biomarkers including neurofilament light (NfL) chain, phosphorylated tau (p-tau), neuroimaging markers, exosomes, metabolomic profiles, and transcriptomic signatures may improve early diagnosis and risk stratification. Several therapeutic approaches, including GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, intranasal insulin, nanoparticle-based delivery systems, stem cell therapies, and bioactive compounds, have demonstrated promising neuroprotective effects in preclinical studies, although clinical translation remains limited. Finally, future studies should be directed toward the use of biomarker-driven diagnosis, clinically relevant disease models, and large-scale clinical studies in order to develop effective therapeutic interventions. Understanding more of the mechanisms that underlie DACD could help inform the creation of precision medicine strategies to prevent or delay diabetes-related cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.